Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.